Okada K, Andoh T
Dept. of Blood Transfusion Hiroshima Univ. Medical Hospital, Japan.
Gan To Kagaku Ryoho. 1991 Aug;18(10):1562-7.
The mechanisms of acquired resistance to mammalian DNA topoisomerase I inhibitor, camptothecin or its derivative (CPT-11) were described. Tumor cell lines containing altered or reduced topoisomerase I were reviewed. It might be necessary to further study on reduced inhibitor uptake and other unknown mechanism.
描述了对哺乳动物DNA拓扑异构酶I抑制剂喜树碱或其衍生物（CPT-11）获得性耐药的机制。对含有改变或减少的拓扑异构酶I的肿瘤细胞系进行了综述。可能有必要进一步研究抑制剂摄取减少及其他未知机制。
